tiprankstipranks
Pieris Pharmaceuticals (PIRS)
NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Price & Analysis

581 Followers

PIRS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$9.31 - $74.40
Previous Close$10.09
Volume13.03K
Average Volume (3M)14.80K
Market Cap
$13.32M
Enterprise Value-$13.04M
Total Cash (Recent Filing)$26.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)
Beta1.40
May 08, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.74
Shares Outstanding1,320,240
10 Day Avg. Volume4,916
30 Day Avg. Volume14,796
Standard Deviation0.24
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.44
Price to Sales (P/S)0.32
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.27
Enterprise Value/Gross Profit-0.31
Enterprise Value/Ebitda-0.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

PIRS FAQ

What was Pieris Pharmaceuticals’s price range in the past 12 months?
Pieris Pharmaceuticals lowest stock price was $9.31 and its highest was $74.40 in the past 12 months.
    What is Pieris Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Pieris Pharmaceuticals’s upcoming earnings report date?
    Pieris Pharmaceuticals’s upcoming earnings report date is May 08, 2024 which is 40 days ago.
      How were Pieris Pharmaceuticals’s earnings last quarter?
      Pieris Pharmaceuticals released its earnings results on Mar 27, 2024. The company reported -$3.706 earnings per share for the quarter, beating the consensus estimate of -$9.6 by $5.894.
        Is Pieris Pharmaceuticals overvalued?
        According to Wall Street analysts Pieris Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Pieris Pharmaceuticals pay dividends?
          Pieris Pharmaceuticals does not currently pay dividends.
          What is Pieris Pharmaceuticals’s EPS estimate?
          Pieris Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Pieris Pharmaceuticals have?
          Pieris Pharmaceuticals has 1,320,240 shares outstanding.
            What happened to Pieris Pharmaceuticals’s price movement after its last earnings report?
            Pieris Pharmaceuticals reported an EPS of -$3.706 in its last earnings report, beating expectations of -$9.6. Following the earnings report the stock price went up 0.906%.
              Which hedge fund is a major shareholder of Pieris Pharmaceuticals?
              Among the largest hedge funds holding Pieris Pharmaceuticals’s share is Platinum Investment Management. It holds Pieris Pharmaceuticals’s shares valued at N/A.
                ---

                Company Description

                Pieris Pharmaceuticals

                Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
                ---

                PIRS Earnings Call

                Q1 2023
                0:00 / 0:00
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Agenus
                Akebia Therapeutics
                Alnylam Pharma
                Avadel Pharmaceuticals
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis